EXPLAINERAn umbrella review of the meta-analyses puts the association at RR 1.45. The AUA's guideline treats ED as a risk marker, and classes shockwave, stem cell and PRP therapy as investigational.
4 min read
WHAT THE STUDY ACTUALLY SAYSA study of 9,248 US women published in May 2026 found perimenopausal women twice as likely to fall into the lowest cardiovascular health band. The design cannot show that the decline happens within individuals.
4 min read
ANALYSISThe randomised evidence in older men found a moderate effect on sexual function and none on vitality or walking. A 5,246-man safety trial cleared it on heart attacks and found more fractures.
4 min read
ANALYSISFine particulate exposure in seven Amazonian capitals was tied to about 5,472 circulatory and 2,621 respiratory deaths over six years. A separate analysis finds cardiac mortality rising with forest loss.
5 min read
WHAT THE STUDY ACTUALLY SAYSThirty-five people received VERVE-102 in a phase 1 trial. The edit is permanent, the follow-up is short, and the endpoint measured was cholesterol, not heart attacks.
4 min read
THE DRUG DOCKETAn individual-participant meta-analysis of 123,940 people in 19 double-blind trials tested 66 label-listed harms. Four survived correction — none of them the ones patients hear about most.
4 min read
ANALYSISCedars-Sinai counted a 118% rise in general-illness visits and a 46% rise in heart attack visits over the 90 days after the fires started. Abnormal blood results more than doubled.
3 min read
ANALYSISHead-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.
4 min read
WHAT THE STUDY ACTUALLY SAYSVESALIUS-CV randomised 12,257 patients with atherosclerosis or diabetes but no prior MI or stroke. Evolocumab reduced the three-point event rate from 8.0% to 6.2% over a median 4.6 years.
3 min read
WHAT THE STUDY ACTUALLY SAYSThe first phase 1 results for CTX310 show gene editing can switch off a lipid gene in the liver. The trial was designed to look for harm, not benefit, and one participant died suddenly.
4 min read
WHAT THE STUDY ACTUALLY SAYSPISCES randomised 1,228 haemodialysis patients in Canada and Australia. The headline hazard ratio of 0.57 counts every event, not just the first — and that choice explains part of the gap.
4 min read